GLPG.AS · Galapagos NV

-

Please sign in to comment on GLPG.AS

1 Comment

Admin

4 years ago

Galapagos NV is currently in a long term downtrend where the price is trading 29.9% below its 200 day moving average.

From a valuation standpoint, the stock is 243.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 9.2.

Galapagos NV's total revenue rose by 0.7% to $144M since the same quarter in the previous year.

Its net income has increased by 49.9% to $-58M since the same quarter in the previous year.

Finally, its free cash flow grew by 49.9% to $-83M since the same quarter in the previous year.

Based on the above factors, Galapagos NV gets an overall score of 3/5.

Exchange	AS
CurrencyCode	EUR
ISIN	BE0003818359
Sector	Healthcare
Industry	Biotechnology

Market Cap	1B
PE Ratio	None
Target Price	31.7
Beta	-0.01
Dividend Yield	None

ABOUT

Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

GLPG.AS · Galapagos NV

-

Galapagos NV

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Galapagos NV using a moving average strategy